All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 2021 TCT Meetings Digital Experience, the GvHD Hub spoke to Muna Qayed, Winship Cancer Institute of Emory University, Atlanta, US. We asked, In what setting is abatacept most effective as GvHD prophylaxis?
In what setting is abatacept most effective as GvHD prophylaxis?
In this video, Qayed discusses a multicenter phase II trial that looks at the addition of abatacept to standard GvHD prophylaxis in patients with hematological malignancies undergoing transplantation. Qayed believes abatacept could significantly open up the donor pool for patients who don't have a well-matched donor in the registry.
Subscribe to get the best content related to GvHD delivered to your inbox